The company has reported zero revenue across the last seven quarters while maintaining a persistent SG&A cost structure that reached $389.2K in 2025Q2.
| Sales/Revenue | 0 | 510.36K | 350.13K | 0 | 0 | 0 |
| Revenue Growth % | - | 45.76% | - | - | - | - |
| Cost of Goods Sold | 0 | 355K | 196.69K | 0 | 0 | 0 |
| COGS % of Revenue | - | 69.56% | 56.17% | - | - | - |
| Gross Profit | 0 | 155.36K | 153.44K | 0 | 0 | 0 |
| Gross Margin % | - | 30.44% | 43.82% | - | - | - |
| Gross Profit Growth % | - | 1.25% | - | - | - | - |
| Operating Expenses | 1.38M | 1.62M | 163.29K | 2.32M | 1.72M | 344.22K |
| OpEx % of Revenue | - | 316.89% | 46.64% | - | - | - |
| Selling, General & Admin | 1.38M | 1.13M | 160.56K | 2.32M | 1.72M | 344.22K |
| SG&A % of Revenue | - | 220.71% | 45.86% | - | - | - |
| Research & Development | 0 | 491.35K | 0 | 0 | 0 | 0 |
| R&D % of Revenue | - | 96.28% | - | - | - | - |
| Other Operating Expenses | 0 | -493 | 2.73K | 0 | 0 | 0 |
| Operating Income | -1.38M | -1.46M | -9.85K | -2.32M | -1.72M | -344.22K |
| Operating Margin % | - | -286.45% | -2.81% | - | - | - |
| Operating Income Growth % | - | -14746.45% | 99.58% | -34.88% | -400.36% | - |
| EBITDA | -2.99M | -1.36M | -7.39K | 3.79M | 8.7M | -2.54M |
| EBITDA Margin % | - | -265.93% | -2.11% | - | - | - |
| EBITDA Growth % | - | -18252.87% | -100.2% | -56.45% | 442.99% | - |
| D&A (Non-Cash Add-back) | 0 | 104.73K | 2.45K | 0 | 0 | 0 |
| EBIT | -2.99M | -1.39M | 19.79K | 3.79M | 8.7M | -2.54M |
| Net Interest Income | 326.75K | 11.04K | -1.85K | 813 | 764 | 178 |
| Interest Income | 326.75K | 11.81K | 290 | 813 | 764 | 178 |
| Interest Expense | 0 | 772 | 2.14K | 0 | 0 | 0 |
| Other Income/Expense | -1.6M | 75.45K | 27.5K | 6.11M | 10.43M | -2.19M |
| Pretax Income | -2.99M | -1.39M | 17.65K | 3.79M | 8.7M | -2.54M |
| Pretax Margin % | - | -271.67% | 5.04% | - | - | - |
| Income Tax | -11.97K | 25.08K | 4.09K | 2.09K | 0 | 0 |
| Effective Tax Rate % | 0.4% | -1.81% | 23.17% | 0.06% | 0% | 0% |
| Net Income | -2.97M | -1.41M | 13.56K | 3.79M | 8.7M | -2.54M |
| Net Margin % | - | -276.58% | 3.87% | - | - | - |
| Net Income Growth % | - | -10509.73% | -99.64% | -56.48% | 442.99% | - |
| Net Income (Continuing) | -2.97M | -1.41M | 13.56K | 3.79M | 8.7M | -2.54M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -0.87 | -0.56 | 0.00 | 0.41 | 0.59 | -0.17 |
| EPS Growth % | - | - | -99.95% | -30.51% | 447.06% | - |
| EPS (Basic) | - | -0.56 | 0.00 | 0.41 | 0.59 | -0.17 |
| Diluted Shares Outstanding | 3.41M | 4.15M | 70.1M | 9.29M | 14.63M | 14.63M |
| Basic Shares Outstanding | 3.41M | 4.15M | 70.1M | 9.29M | 14.63M | 14.63M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Critical liquidity and financing
As indicated by the provided financial data, YDES has reported zero revenue across the last seven quarters, suggesting that the company remains in a pre-commercial phase where top-line growth is non-existent and entirely dependent on future clinical milestones or potential licensing agreements yet to materialize.
The absence of consistent revenue generation highlights the speculative nature of the firm's current business model. Investors should monitor whether the company can transition from its current R&D-heavy posture to a commercial stage, as the lack of historical growth metrics makes forecasting future performance extremely difficult.
Based on the reported income statement figures, YDES continues to incur significant SG&A expenses, reaching $389.2K in 2025Q2, which underscores a persistent cost structure that is not currently being offset by any meaningful revenue streams or commercial activity within the diagnostic testing segment.
The company's reliance on SG&A spending without corresponding revenue suggests that capital is being consumed primarily for administrative and operational overhead rather than direct clinical output. This cost structure warrants further investigation into whether management can achieve necessary expense discipline before the current cash reserves are fully depleted.
According to the quarterly income statements, YDES has experienced extreme fluctuations in net income, including a $17.1M gain in 2024Q2 followed by a $22.0M loss in 2024Q1, which suggests that reported earnings are driven by non-operating items rather than core business performance.
These erratic swings in net income appear to be disconnected from the company's underlying operational progress, likely reflecting accounting adjustments or one-time financial events. Analysts should look past these headline figures to focus on the persistent operating losses, which provide a more accurate view of the company's current financial health.
As reported in financial statements, the company maintains a precarious financial position with a cash balance of only $3.1M, which appears insufficient to cover the ongoing operating losses and high burn rate required to sustain its exosome-based diagnostic platform development over the next twelve months.
The combination of zero revenue and consistent quarterly operating losses suggests that the company may be forced to seek dilutive financing in the near term. Investors should consider the high probability of a liquidity event, as the current cash position provides little buffer against potential regulatory or clinical delays.
Quick answers to the most common questions about buying YDES stock.
For fiscal year 2024, YD Bio Limited Ordinary Shares (YDES) reported total revenue of $0.5M.
YD Bio Limited Ordinary Shares (YDES) reported a net loss of $1.4M for the fiscal year ending 2024.
YD Bio Limited Ordinary Shares (YDES) reported an operating income of $-1.5M, resulting in an operating profit margin of -286.5%. This margin reflects the operational efficiency of the business before interest and taxes.
YD Bio Limited Ordinary Shares (YDES) generated $0.2M in gross profit for the year, representing a gross profit margin of 30.4%. This demonstrates the company's core pricing power and production efficiency.